Erschienen in:
26.07.2022 | ASO Research Letter
Soluble E-Cadherin as a Potential Biomarker in Hereditary Diffuse Gastric Cancer Syndrome
verfasst von:
Martha E. Teke, MD, Lauren A. Gamble, MD, Sarah G. Samaranayake, MS, Benjamin L. Green, MD, Areeba Saif, MD, Jonathan M. Hernandez, MD, Jeremy L. Davis, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 13/2022
Einloggen, um Zugang zu erhalten
Excerpt
Hereditary diffuse gastric cancer (HDGC) syndrome, caused by inactivating germline variants in the
CDH1 tumor suppressor gene, confers an elevated lifetime gastric cancer risk of 25–42%.
1 Multifocal, occult SRC carcinomas are identified in nearly all prophylactic total gastrectomy explants from asymptomatic
CDH1 variant carriers.
2 These intramucosal SRC foci exhibit indolent behavior, and the specific molecular alterations underpinning cancer progression are yet to be unveiled.
1 As such, risk-reducing total gastrectomy is recommended for all germline
CDH1 variant carriers with family history of diffuse gastric cancer (DGC) starting at age 20 years.
3 Total gastrectomy carries significant risk, potential morbidity, and lifestyle change. Therefore, a critical need exists for early, noninvasive means of prognostication for this rare patient population. …